Sexual Dysfunction

The AUA 2018 sexual dysfunction take-home messages also included a novel end-to-side nerve grafting procedure for men with post-radical-prostatectomy ED as well as the finding that use of a selective serotonin reuptake inhibitor or serotonin-norepinephrine reuptake inhibitor does not appear to change the adverse effect profile of flibanserin (Addyi).

To help you sift the enormous scientific program and prioritize your schedule at the AUA annual meeting, the editors have called upon Urology Times’ editorial advisory board to identify the key research across multiple areas of the specialty.

In this article, we describe our thought processes in treating patients with Peyronie's disease, which are summarized in an algorithm.

There are no national or international guidelines regarding penile transplants, raising a question without a concrete answer: What are the rules and the limits?

"[Penile transplantation] is a real advance for patients who have a penile deficiency or penile loss," says Arthur L. Burnett, II, MD, MBA.

While urologists are generally comfortable discussing patients’ sexual orientation, they report that both their knowledge of care of transgender patients and training in such care are lacking.

It’s hard to argue against an erectile dysfunction treatment that is potentially disease modifying, is noninvasive, and seems to do no harm. The treatment, low-intensity shock wave therapy, has yet to earn the FDA’s approval but is widely used in other countries. Early results from ongoing U.S. trials are promising.

Other products and services discussed in this round-up include a biosimilar for cancer, an American College of Surgeons manual on quality initiatives, a kidney cancer microsite, and more.

Other pipeline developments include an agent to control pain in IC/BPS patients, an antibody to treat prostate and bladder cancer, an injectable OAB treatment, and more.

Other products discussed include cancer tests, an app to connect patients with specialists, a revenue management system, and more

Other pipeline developments include a new company formed to develop OAB treatments, a phase III urothelial cancer study meeting its primary endpoint, the formation of a partnership to study RCC treatment, and more.

Findings of an ecologic study indicate that direct-to-consumer advertising for testosterone therapy influenced men to seek treatment and was accompanied by increased testosterone prescribing, including initiation in men without clear indications for use.

In these videos, expert surgeons demonstrate robot-assisted penile inversion vaginoplasty, single-stage metoidioplasty, and simple orchiectomy for transgender patients.

Other pipeline developments include efficacy results for a bladder and prostate cancer drug, an infertility tool to predict sperm quality, the initiation of an immunotherapy combination for mUC, and more.

Recently published studies also evaluated testosterone replacement therapy’s effect on anemia, cognitive function, and bone density and strength.

Abraham Morgentaler, MD, shares why the recent publication of five studies on testosterone therapy in JAMA and JAMA Internal Medicine "was arguably the most important week ever for the science of testosterone therapy and its impact on men's health."

Urology-related FDA approvals from 2016 encompassed drugs and devices for prostate cancer, renal cell carcinoma, bladder cancer, stone disease, and more.

Other products discussed include an updated prostate tissue ablation device, a contrast agent for voiding ultrasonography, a bladder cancer test and more.

Other pipeline developments discussed include an implantable device for OAB treatment, a subcutaneous hypogonadism treatment, efficacy results for an HPV drug, and the status of a device-based BPH treatment.

Other products discussed include a stent system for treating ureteral obstructions, a male infertility test, and more.

Overweight and obese men who participated in 12 weeks of aerobic exercise saw significantly increased testosterone levels, a recent study found.

Researchers evaluated mean hematocrit before and after pellet implantation in a cohort of 97 patients.

Other pipeline developments discussed include a bladder cancer test, a male infertility assay, and the first oral dosage treatment for hypogonadism.

Testosterone replacement therapy may not have the benefit many physicians think it does-particularly for women grappling with sexual dysfunction.

Other new products discussed in this article include a surgical training model, devices designed to improve prostate biopsy accuracy, an updated label and more.

Testosterone therapy in hypogonadal men with prostate cancer who have had definitive treatment and in those on surveillance appears to be safe, according to a new study.

Urologists need to “be aware of the role and impact of [anabolic-androgenic steroid] use in our patient population,” says men’s health expert James M. Hotaling, MD, MS.

Although a recent study of testosterone therapy does not fulfill the need for large-scale, randomized, controlled studies of the treatment, “it is very informative in several ways,” writes Arthur L. Burnett, II, MD, MBA.